Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study
- 1 May 2017
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 62, 41-45
Abstract
No abstract availableKeywords
Funding Information
- NIMH (MH-94268)
This publication has 20 references indexed in Scilit:
- The human gut mycobiome: pitfalls and potentials—a mycologist’s perspectiveMycologia, 2015
- Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controlsPeerJ, 2015
- The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic reviewPathologie Biologie, 2015
- Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled TrialBiomarker Insights, 2015
- C-reactive protein is elevated in schizophreniaSchizophrenia Research, 2013
- Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviourNature Reviews Neuroscience, 2012
- Gastrointestinal inflammation and associated immune activation in schizophreniaSchizophrenia Research, 2012
- Candida albicans, a major human fungal pathogenJournal of Microbiology, 2011
- Characterization of the Oral Fungal Microbiome (Mycobiome) in Healthy IndividualsPLOS Pathogens, 2010
- Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.Gut, 1990